nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—EDNRB—Endothelin Pathways—ADCY10—nephrolithiasis	0.0725	0.25	CbGpPWpGaD
Sitaxentan—Fibromyalgia—Hydrochlorothiazide—nephrolithiasis	0.069	0.103	CcSEcCtD
Sitaxentan—EDNRA—Endothelin Pathways—ADCY10—nephrolithiasis	0.0519	0.179	CbGpPWpGaD
Sitaxentan—Localised oedema—Hydrochlorothiazide—nephrolithiasis	0.0342	0.051	CcSEcCtD
Sitaxentan—Blood potassium increased—Hydrochlorothiazide—nephrolithiasis	0.0286	0.0426	CcSEcCtD
Sitaxentan—Cardiac murmur—Hydrochlorothiazide—nephrolithiasis	0.0279	0.0415	CcSEcCtD
Sitaxentan—Raised liver function tests—Hydrochlorothiazide—nephrolithiasis	0.0187	0.0279	CcSEcCtD
Sitaxentan—Sinus bradycardia—Hydrochlorothiazide—nephrolithiasis	0.0176	0.0263	CcSEcCtD
Sitaxentan—Peptic ulcer—Hydrochlorothiazide—nephrolithiasis	0.0129	0.0193	CcSEcCtD
Sitaxentan—Nephritis interstitial—Hydrochlorothiazide—nephrolithiasis	0.0128	0.0191	CcSEcCtD
Sitaxentan—Blood creatine phosphokinase increased—Hydrochlorothiazide—nephrolithiasis	0.0126	0.0187	CcSEcCtD
Sitaxentan—Tubulointerstitial nephritis—Hydrochlorothiazide—nephrolithiasis	0.0113	0.0168	CcSEcCtD
Sitaxentan—Feeling hot—Hydrochlorothiazide—nephrolithiasis	0.011	0.0164	CcSEcCtD
Sitaxentan—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.011	0.0164	CcSEcCtD
Sitaxentan—EDNRB—G alpha (q) signalling events—DGKH—nephrolithiasis	0.0104	0.0358	CbGpPWpGaD
Sitaxentan—CYP2C19—urine—nephrolithiasis	0.00991	0.26	CbGeAlD
Sitaxentan—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.00964	0.0144	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Other—CHRM3—nephrolithiasis	0.00957	0.033	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.0093	0.032	CbGpPWpGaD
Sitaxentan—Gout—Hydrochlorothiazide—nephrolithiasis	0.00926	0.0138	CcSEcCtD
Sitaxentan—Hypercholesterolaemia—Hydrochlorothiazide—nephrolithiasis	0.00914	0.0136	CcSEcCtD
Sitaxentan—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.00881	0.0131	CcSEcCtD
Sitaxentan—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.00875	0.013	CcSEcCtD
Sitaxentan—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00865	0.0129	CcSEcCtD
Sitaxentan—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.0085	0.0126	CcSEcCtD
Sitaxentan—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.0084	0.0125	CcSEcCtD
Sitaxentan—CYP2C9—urine—nephrolithiasis	0.00769	0.202	CbGeAlD
Sitaxentan—EDNRB—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00752	0.0259	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00744	0.0256	CbGpPWpGaD
Sitaxentan—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00725	0.0108	CcSEcCtD
Sitaxentan—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00708	0.0105	CcSEcCtD
Sitaxentan—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.00689	0.0103	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00672	0.0232	CbGpPWpGaD
Sitaxentan—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.00668	0.00995	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00665	0.0229	CbGpPWpGaD
Sitaxentan—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00665	0.0099	CcSEcCtD
Sitaxentan—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.00662	0.00986	CcSEcCtD
Sitaxentan—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.0066	0.00982	CcSEcCtD
Sitaxentan—EDNRB—cortex of kidney—nephrolithiasis	0.00647	0.17	CbGeAlD
Sitaxentan—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.00646	0.00962	CcSEcCtD
Sitaxentan—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00628	0.00935	CcSEcCtD
Sitaxentan—Migraine—Hydrochlorothiazide—nephrolithiasis	0.00618	0.0092	CcSEcCtD
Sitaxentan—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.0059	0.00879	CcSEcCtD
Sitaxentan—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00588	0.00876	CcSEcCtD
Sitaxentan—CYP3A4—urine—nephrolithiasis	0.00586	0.154	CbGeAlD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00581	0.02	CbGpPWpGaD
Sitaxentan—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.0058	0.00863	CcSEcCtD
Sitaxentan—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00575	0.00857	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00573	0.00854	CcSEcCtD
Sitaxentan—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00573	0.00854	CcSEcCtD
Sitaxentan—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00567	0.00845	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00565	0.00842	CcSEcCtD
Sitaxentan—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00565	0.00842	CcSEcCtD
Sitaxentan—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.00554	0.00824	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00554	0.00824	CcSEcCtD
Sitaxentan—EDNRA—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00538	0.0185	CbGpPWpGaD
Sitaxentan—EDNRA—cortex of kidney—nephrolithiasis	0.00535	0.14	CbGeAlD
Sitaxentan—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00529	0.00787	CcSEcCtD
Sitaxentan—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00507	0.00755	CcSEcCtD
Sitaxentan—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00501	0.00746	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00498	0.0172	CbGpPWpGaD
Sitaxentan—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00495	0.00737	CcSEcCtD
Sitaxentan—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00489	0.00729	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00481	0.0166	CbGpPWpGaD
Sitaxentan—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00477	0.0071	CcSEcCtD
Sitaxentan—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00476	0.00708	CcSEcCtD
Sitaxentan—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00474	0.00706	CcSEcCtD
Sitaxentan—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00472	0.00702	CcSEcCtD
Sitaxentan—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.0047	0.007	CcSEcCtD
Sitaxentan—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00461	0.00687	CcSEcCtD
Sitaxentan—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00456	0.00679	CcSEcCtD
Sitaxentan—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00454	0.00676	CcSEcCtD
Sitaxentan—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00442	0.00658	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—RGS14—nephrolithiasis	0.00439	0.0151	CbGpPWpGaD
Sitaxentan—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00435	0.00648	CcSEcCtD
Sitaxentan—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00434	0.00647	CcSEcCtD
Sitaxentan—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00428	0.00637	CcSEcCtD
Sitaxentan—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00419	0.00623	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00416	0.0143	CbGpPWpGaD
Sitaxentan—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00405	0.00603	CcSEcCtD
Sitaxentan—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00403	0.006	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—RGS14—nephrolithiasis	0.00398	0.0137	CbGpPWpGaD
Sitaxentan—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00384	0.00571	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—CHRM3—nephrolithiasis	0.00379	0.0131	CbGpPWpGaD
Sitaxentan—Tension—Hydrochlorothiazide—nephrolithiasis	0.00371	0.00552	CcSEcCtD
Sitaxentan—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00367	0.00547	CcSEcCtD
Sitaxentan—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00363	0.00541	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00356	0.0123	CbGpPWpGaD
Sitaxentan—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00354	0.00527	CcSEcCtD
Sitaxentan—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00351	0.00522	CcSEcCtD
Sitaxentan—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00349	0.0052	CcSEcCtD
Sitaxentan—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00347	0.00517	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—PTH—nephrolithiasis	0.00347	0.0119	CbGpPWpGaD
Sitaxentan—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00341	0.00508	CcSEcCtD
Sitaxentan—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.0034	0.00506	CcSEcCtD
Sitaxentan—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00338	0.00504	CcSEcCtD
Sitaxentan—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00322	0.00479	CcSEcCtD
Sitaxentan—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00318	0.00473	CcSEcCtD
Sitaxentan—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00315	0.00469	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—RGS14—nephrolithiasis	0.00314	0.0108	CbGpPWpGaD
Sitaxentan—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00311	0.00463	CcSEcCtD
Sitaxentan—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00309	0.00459	CcSEcCtD
Sitaxentan—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00302	0.0045	CcSEcCtD
Sitaxentan—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00301	0.00448	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—DGKH—nephrolithiasis	0.00296	0.0102	CbGpPWpGaD
Sitaxentan—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00294	0.00438	CcSEcCtD
Sitaxentan—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00288	0.00429	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—RGS14—nephrolithiasis	0.00285	0.00983	CbGpPWpGaD
Sitaxentan—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00279	0.00415	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—ADCY10—nephrolithiasis	0.00277	0.00954	CbGpPWpGaD
Sitaxentan—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00274	0.00408	CcSEcCtD
Sitaxentan—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00272	0.00404	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—CHRM3—nephrolithiasis	0.00271	0.00935	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—DGKH—nephrolithiasis	0.00269	0.00927	CbGpPWpGaD
Sitaxentan—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00268	0.00399	CcSEcCtD
Sitaxentan—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00266	0.00396	CcSEcCtD
Sitaxentan—Pain—Hydrochlorothiazide—nephrolithiasis	0.00264	0.00393	CcSEcCtD
Sitaxentan—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00264	0.00393	CcSEcCtD
Sitaxentan—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00254	0.00379	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—PTH—nephrolithiasis	0.00248	0.00855	CbGpPWpGaD
Sitaxentan—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00245	0.00365	CcSEcCtD
Sitaxentan—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00244	0.00363	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—RGS14—nephrolithiasis	0.00235	0.00811	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00227	0.00338	CcSEcCtD
Sitaxentan—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00221	0.0033	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00214	0.00738	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—DGKH—nephrolithiasis	0.00212	0.00731	CbGpPWpGaD
Sitaxentan—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00211	0.00314	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—SLC26A1—nephrolithiasis	0.00211	0.00726	CbGpPWpGaD
Sitaxentan—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00204	0.00304	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—ADCY10—nephrolithiasis	0.00198	0.00683	CbGpPWpGaD
Sitaxentan—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00196	0.00292	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—PTH—nephrolithiasis	0.00196	0.00675	CbGpPWpGaD
Sitaxentan—Rash—Hydrochlorothiazide—nephrolithiasis	0.00195	0.0029	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—CHRM3—nephrolithiasis	0.00195	0.0067	CbGpPWpGaD
Sitaxentan—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00194	0.00289	CcSEcCtD
Sitaxentan—Headache—Hydrochlorothiazide—nephrolithiasis	0.00193	0.00288	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—DGKH—nephrolithiasis	0.00193	0.00664	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—SLC26A1—nephrolithiasis	0.00192	0.00662	CbGpPWpGaD
Sitaxentan—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00183	0.00273	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—PTH—nephrolithiasis	0.00178	0.00613	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RGS14—nephrolithiasis	0.00168	0.0058	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00159	0.00548	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—DGKH—nephrolithiasis	0.00159	0.00548	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00153	0.00528	CbGpPWpGaD
Sitaxentan—CYP3A4—renal system—nephrolithiasis	0.00143	0.0376	CbGeAlD
Sitaxentan—EDNRA—GPCR downstream signaling—PTH—nephrolithiasis	0.0014	0.00483	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CHRM3—nephrolithiasis	0.00139	0.0048	CbGpPWpGaD
Sitaxentan—CYP3A4—kidney—nephrolithiasis	0.00139	0.0364	CbGeAlD
Sitaxentan—EDNRA—Signaling by GPCR—PTH—nephrolithiasis	0.00127	0.00439	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.00127	0.00436	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CHRM3—nephrolithiasis	0.00115	0.00396	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00114	0.00392	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—DGKH—nephrolithiasis	0.00114	0.00392	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PTH—nephrolithiasis	0.00105	0.00362	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CHRM3—nephrolithiasis	0.000822	0.00283	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTH—nephrolithiasis	0.000752	0.00259	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SPP1—nephrolithiasis	0.000528	0.00182	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GRHPR—nephrolithiasis	0.000475	0.00164	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GRHPR—nephrolithiasis	0.000433	0.00149	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AGXT—nephrolithiasis	0.000424	0.00146	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AGXT—nephrolithiasis	0.000386	0.00133	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SPP1—nephrolithiasis	0.000378	0.0013	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC26A1—nephrolithiasis	0.00036	0.00124	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—APRT—nephrolithiasis	0.00036	0.00124	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—APRT—nephrolithiasis	0.000328	0.00113	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC26A1—nephrolithiasis	0.000328	0.00113	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000286	0.000985	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AQP1—nephrolithiasis	0.000257	0.000884	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—AGXT—nephrolithiasis	0.000255	0.000878	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AQP1—nephrolithiasis	0.000234	0.000806	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CHRM3—nephrolithiasis	0.000232	0.0008	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	0.000217	0.000746	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—APRT—nephrolithiasis	0.000217	0.000746	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CHRM3—nephrolithiasis	0.000212	0.000729	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—AQP1—nephrolithiasis	0.000154	0.000532	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CHRM3—nephrolithiasis	0.00014	0.000481	CbGpPWpGaD
